Acquired alterations in CRBN and CUL4B due to iMiD therapies not only have relevance to MM treatment but also presage analogous mutations that are likely to be acquired based on various proteolysis targeting chimera (PROTAC) therapies under development48. Here, CUL4B is linked to Miyoshi myopathy.